Robbins Geller Rudman & Dowd LLP Announces Chance for Traders with Significant Losses to Lead the Athira Pharma, Inc. Course Action Lawsuit

SAN DIEGO, July 16, 2021 (Globe NEWSWIRE) — The Athira Pharma class motion lawsuit fees Athira Pharma, Inc. (NASDAQ: ATHA) and its CEO with violations of the Securities Trade Act of 1934 and seeks to signify purchasers of Athira Pharma securities among September 18, 2020 and June 17, 2021, inclusive (the “Class Period”). The Athira Pharma course action lawsuit was commented in the Western District of Washington and is captioned Wang v. Athira Pharma, Inc., No. 21-cv-00861. Two comparable lawsuits – Jawandha v. Athira Pharma, Inc., No. 21-cv-00862, and Slyne v. Athira Pharma, Inc., No. 21-cv-00864 – are also pending in the Western District of Washington.

If you suffered substantial losses and would like to provide as guide plaintiff of the Athira Pharma class motion lawsuit, make sure you present your details by clicking below. You can also make contact with legal professional J.C. Sanchez of Robbins Geller by calling 800/449-4900 or through e-mail at [email protected]. Guide plaintiff motions for the Athira Pharma course motion lawsuit have to be filed with the courtroom no later than August 24, 2021.

Situation ALLEGATIONS: The Athira Pharma class action lawsuit alleges that, during the Course Interval, defendants built fake and deceptive statements and unsuccessful to disclose that: (i) the study carried out by Athira Pharma’s President and Main Executive Officer, defendant Leen Kawas, which formed the basis for Athira Pharma’s products candidates and mental property, was tainted by Kawas’s scientific misconduct, including the manipulation of essential details and (ii) as a end result, defendants’ constructive statements about Athira Pharma’s company, functions, and potential customers had been materially misleading and omitted substance facts required to make the statements manufactured not deceptive.

On June 17, 2021, Athira Pharma issued a push launch asserting that Athira Pharma’s Board of Administrators had put Kawas on non permanent depart pending a evaluation of actions stemming from doctoral investigate Kawas conducted when at Washington Condition College. An posting posted in STAT News afterwards that day discovered that the investigation of Kawas similar to allegations that she altered photographs in 4 separate papers relating to her analysis on hepatocyte progress issue (HGF), a protein with the likely to deal with Alzheimer’s illness and other neurological disorders. The posting noted that while Athira Pharma “has given that moved on to a diverse molecule than the just one Kawas was doing the job on, it nevertheless aims to goal HGF. And so Kawas’s doctoral work laid the biological groundwork that Athira carries on to use in their tactic to treating Alzheimer’s.” On this news, Athira Pharma’s stock value fell by almost 39%, harming investors.

Tale proceeds

THE Lead PLAINTIFF Method: The Private Securities Litigation Reform Act of 1995 permits any trader who procured Athira Pharma securities through the Course Interval to find appointment as lead plaintiff in the Athira Pharma class motion lawsuit. A lead plaintiff is generally the movant with the greatest financial desire in the aid sought by the putative course who is also typical and enough of the putative class. A guide plaintiff acts on behalf of all other course members in directing the Athira Pharma class motion lawsuit. The guide plaintiff can select a law company of its alternative to litigate the Athira Pharma class motion lawsuit. An investor’s skill to share in any possible upcoming recovery of the Athira Pharma course action lawsuit is not dependent upon serving as direct plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 workplaces nationwide, Robbins Geller Rudman & Dowd LLP is the greatest U.S. legislation organization symbolizing buyers in securities course actions. Robbins Geller attorneys have obtained numerous of the greatest shareholder recoveries in record, which includes the major securities course action recovery at any time – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Motion Companies Top 50 Report ranked Robbins Geller very first for recovering $1.6 billion for investors final yr, extra than double the quantity recovered by any other securities plaintiffs’ firm. Please pay a visit to https://www.rgrdlaw.com/firm.html for additional data.

Legal professional marketing.
Earlier outcomes do not assure long run outcomes.
Services may possibly be carried out by lawyers in any of our places of work.

Speak to:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]